Last reviewed · How we verify
CBD-THC-Piperine-PNL capsule
At a glance
| Generic name | CBD-THC-Piperine-PNL capsule |
|---|---|
| Also known as | Cannabidiol and dronabinol in ProNanoLiposphere formulation |
| Sponsor | Hadassah Medical Organization |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers (PHASE1)
- Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBD-THC-Piperine-PNL capsule CI brief — competitive landscape report
- CBD-THC-Piperine-PNL capsule updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI